Takeda Pharmaceutical Company Limited Share Price
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,540.00 JPY | +2.12% |
|
+0.49% | +14.58% |
| 08-06 | Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL | MT |
| 08-06 | Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1 | CI |
| Market Cap | 8,846B 56.09B 48.52B 45.31B 41.57B 78.18B 5,339B 79.42B 532B 209B 2,676B 211B 206B | P/E 2027 * |
44.5x | P/E 2028 * | 27.6x |
|---|---|---|---|---|---|
| Enterprise Value | 12,772B 80.99B 70.06B 65.42B 60.02B 113B 7,708B 115B 768B 301B 3,863B 304B 297B | EV / Sales 2027 * |
2.74x | EV / Sales 2028 * | 2.66x |
| Free-Float |
99.28% | Yield 2027 * |
3.69% | Yield 2028 * | 3.76% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +2.12% | ||
| 1 week | +0.49% | ||
| Current month | +0.49% | ||
| 1 month | +1.69% | ||
| 3 months | +4.33% | ||
| 6 months | +0.42% | ||
| Current year | +14.58% |
| 1 week | 5,225 |  | 5,541 |
| 1 month | 5,225 | | 5,903 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 23/06/2026 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 31/03/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 31/05/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 31/12/2018 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 31/05/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% | ||
| 10/07/26 | Issuer sale | President, Japan Pharma B.U. | -1,022 | 0.0001% | ||
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.12% | +0.49% | +30.97% | +26.69% | 56.09B | |
| -0.52% | +3.21% | +85.02% | +161.12% | 1,057B | |
| +0.88% | +1.13% | +51.13% | +49.76% | 625B | |
| +0.89% | -1.95% | +23.73% | +63.67% | 435B | |
| +0.71% | +3.87% | +47.45% | +38.68% | 363B | |
| +0.64% | -0.49% | +35.39% | +40.21% | 296B | |
| +0.39% | -5.83% | +8.64% | +9.28% | 249B | |
| +1.51% | +6.69% | +44.34% | +62.47% | 222B | |
| +3.92% | -0.46% | -1.21% | -44.09% | 209B | |
| +1.80% | +2.30% | +20.79% | +65.13% | 165B | |
| Average | +1.39% | +0.83% | +34.62% | +47.29% | 367.69B | |
| Weighted average by Cap. | +1.14% | +1.21% | +48.07% | +74.59% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,668B 29.6B 25.61B 23.91B 21.94B 41.26B 2,817B 41.91B 281B 110B 1,412B 111B 109B | 4,747B 30.1B 26.04B 24.32B 22.31B 41.95B 2,865B 42.62B 285B 112B 1,436B 113B 111B |
| Net income | 191B 1.21B 1.05B 976M 896M 1.68B 115B 1.71B 11.46B 4.5B 57.66B 4.54B 4.44B | 316B 2.01B 1.73B 1.62B 1.49B 2.8B 191B 2.84B 19.01B 7.46B 95.68B 7.53B 7.37B |
| Net Debt | 3,926B 24.9B 21.54B 20.11B 18.45B 34.7B 2,370B 35.25B 236B 92.61B 1,188B 93.49B 91.45B | 3,764B 23.87B 20.65B 19.28B 17.69B 33.27B 2,272B 33.8B 226B 88.79B 1,139B 89.64B 87.68B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/08/26 | JP¥5,540.00 | +2.12% | 4,116,100 |
| 06/08/26 | JP¥5,425.00 | +2.96% | 4,077,000 |
| 05/08/26 | JP¥5,269.00 | -0.32% | 3,470,800 |
| 04/08/26 | JP¥5,286.00 | -2.26% | 3,851,800 |
| 03/08/26 | JP¥5,408.00 | -1.90% | 4,750,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
